Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Century Therapeutics ( (IPSC) ) has shared an update.
On March 12, 2026, Century Therapeutics reported its full-year 2025 results, highlighting progress on CNTY-813, a beta islet replacement therapy for type 1 diabetes, and CNTY-308, a CD19-targeted CAR-iT cell candidate for B-cell-mediated diseases. CNTY-813 showed compelling preclinical data, including over six months of normoglycemia in animal models and completion of a GMP master cell bank, with the company targeting an IND filing in the fourth quarter of 2026 and initial clinical data in the second half of 2027.
CNTY-308 remained on track for first-in-human studies in 2026 after demonstrating functional comparability to primary CAR-T cells, while additional data from the CNTY-101 CARAMEL investigator-sponsored autoimmune study are expected during 2026. Financially, Century cut its 2025 net loss to $9.6 million from $126.6 million in 2024, driven by a jump in Bristol-Myers Squibb collaboration revenue and lower R&D and G&A expenses, and an oversubscribed $135 million private placement in January 2026 extended its cash runway into the first quarter of 2029.
The most recent analyst rating on (IPSC) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.
Spark’s Take on IPSC Stock
According to Spark, TipRanks’ AI Analyst, IPSC is a Neutral.
The score is held back mainly by persistent, significant cash burn and ongoing losses despite a decent balance-sheet position. Technicals are supportive but appear overbought, while valuation lacks earnings/dividend support; offsetting these, corporate events (Nasdaq compliance and new financing) improve near-term financial flexibility.
To see Spark’s full report on IPSC stock, click here.
More about Century Therapeutics
Century Therapeutics, Inc. (NASDAQ: IPSC) is a biotechnology company developing induced pluripotent stem cell (iPSC)-derived, off-the-shelf cell therapies targeting autoimmune diseases, including type 1 diabetes, and cancer. Its pipeline leverages an iPSC cell foundry and proprietary Allo-Evasion immune-evasion engineering to expand patient access and provide advantages over existing cell therapies.
Average Trading Volume: 1,874,082
Technical Sentiment Signal: Buy
Current Market Cap: $490.4M
For detailed information about IPSC stock, go to TipRanks’ Stock Analysis page.